JPRN-UMIN000009340招募中2 期
Phase II Feasibility study of Weekly Amrubicin in Patients with Previously Treated Non-small Cell Lung Cancer - Weekly Amrubicin in Previously Treated Non-small Cell Lung Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with active severe infections (2) Patients with cardiac infarction or necessary cardiac function abnormality of the treatment (3) Patients with active interstitial pneumonia recognized by chest X-ray or chest CT (4) Received the maximum allowed cumulative dose of cardiotoxic drugs such as anthracycline derivatives in prior therapy (5) Inappropriate patients for this study judged by the physicians
研究者
相似试验
已完成
2 期
Phase II study of weekly amrubicin in patients with refractory or relapsed non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000002570ational Hospital Organization Nagoya Medical Center43
已完成
2 期
Phase II study of amrubicin monotherapy for treating elderly and poor-risk patients with small-cell lung cancer.small cell lung cancerJPRN-UMIN000011055Kitasato University School of Medicine Department of Respiratory Medicine34
已完成
2 期
A phase II study of amrubicin for previously treated small cell lung cancerFor patients with recurrent small cell lung cancerJPRN-UMIN000001752Gunma University Hospital35
已完成
2 期
Phase II study of amrubicin for previously treated advanced non-small cell lung cancerRecurrent non-small cell lung cancerJPRN-UMIN000001751Gunma University Hospital35
进行中（未招募）
不适用
Randomized phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC ES - NDPatient with small cell lung cancer.MedDRA version: 6.1Level: PTClassification code 10041068EUCTR2006-001956-11-ITCABRELLIS PHARMACEUTICALS CORPORATIO85